EUDA Health Holdings Ltd
No enriched coverage for $EUDA in the last 7 days.
No SEC Form 4 filings for $EUDA in the last 30 days.
See all $EUDA insider activity →EUDA Health Holdings reported a GAAP EPS of -$0.33 and revenue of $3.06M for the first half, a 11.8% year-over-year decline. The company's stock price fell 1.84% following the earnings release.
EUDA Health Holdings (NASDAQ: EUDA) said it signed a tri-party memorandum of understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on developing, manufacturing, and commercializing next-generation iPSC-derived off-the-shelf oncology cell therapies. The company framed the deal as advancing its commercialization and distribution strategy.
EUDA Health Holdings (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider focusing on longevity and preventive health in Asia, with operations in Singapore, Malaysia, China, and expanding into India. The company is developing stem cell therapy platforms, launching consumer wellness products like EUDA Helixé, and integrating a digital health and rewards ecosystem using a QB utility token. Additionally, EUDA also manages a property management business in Singapore and utilizes various financing instruments to support its growth.
Recent EUDA coverage spans financial news and earnings.
The negative earnings and revenue miss suggest short-term downside pressure.
The MOU is a positive strategic signal for EUDA’s pipeline and commercialization ambitions, but it is not a binding deal or clinical/financial milestone.
EUDA Health Holdings exhibits growth potential driven by its expansion into digital health and wellness markets, with ongoing development of stem cell therapies and consumer products. The company's diversified operations and strategic initiatives suggest a positive outlook, though valuation and execution risks remain.
EUDA's potential acquisition of GO POSB indicates a strategic expansion in healthcare services, which could positively influence EUDA's stock performance.
EUDA Health Holdings Limited has signed a Letter of Intent to acquire Chemokine Pte Ltd, signaling potential expansion in healthcare services and strategic growth.
AlphAI scores every news story that mentions EUDA with an AI model for sentiment and relevance, and aggregates insider trades from EUDA Health Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
EUDA Health Holdings reported a GAAP EPS of -$0.33 and revenue of $3.06M for the first half, a 11.8% year-over-year decline. The company's stock price fell 1.84% following the earnings release.
1 min readEUDA Health Holdings (NASDAQ: EUDA) said it signed a tri-party memorandum of understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on developing, manufacturing, and commercializing next-generation iPSC-derived off-the-shelf oncology cell therapies. The company framed the deal as advancing its commercialization and distribution strategy.
2 min readEUDA Health Holdings (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider focusing on longevity and preventive health in Asia, with operations in Singapore, Malaysia, China, and expanding into India. The company is developing stem cell therapy platforms, launching consumer wellness products like EUDA Helixé, and integrating a digital health and rewards ecosystem using a QB utility token. Additionally, EUDA also manages a property management business in Singapore and utilizes various financing instruments to support its growth.
5 min readSINGAPORE, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- EUDA Health Holdings Limited ( NASDAQ: EUDA ) ( "EUDA" or the "Company" ) , a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte.
3 min readSINGAPORE, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- EUDA Health Holdings Limited EUDA ( "EUDA" or the "Company" ) , a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent ( the "LOI" ) to ...
2 min read